Results 101 to 110 of about 985,610 (254)
Addiction, EarlyView.Abstract Background and aims The market for new psychoactive substances (NPS) is highly dynamic, with hundreds of substances emerging on the European drug market in the last decade. 3‐methylmethcathinone (3‐MMC), a synthetic cathinone and isomer of mephedrone (4‐MMC), gained popularity in the Netherlands due to its psychostimulant effects and initial ...
Nadia Robert Petronella Wilhelmina Hutten +4 more
wiley +1 more source
Synthetic Cannabinoids: A Bibliometric Analysis
Aim: Synthetic cannabinoids (SC) are one of the fastest-spreading and most concerning classes of new psychoactive substances. Originally synthesized for scientific research, these compounds have rapidly begun to be abused due to their potent psychoactive
Muhammed Emin Parlak +2 more
core +1 more source
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids
The Journal of Emergency Medicine, 2013 Cannabinoid hyperemesis syndrome (CHS) was initially described in 2004 and remains an under-recognized clinical entity that occurs in chronic heavy marijuana smokers.We describe the first report of CHS in an abuser of synthetic cannabinoids. CHS is thought to be caused by over-stimulation of the cannabinoid 1 receptor.
unknown ( host institution ) +1 more
openaire +3 more sources
Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA
Addiction, EarlyView.Abstract Background and aims Adolescent substance use is a significant public health concern, though the scope of the problem is difficult to ascertain given reliance on self‐reported substance use information. Recent, large cohort studies in adolescents and young adults suggest underreporting of substance use.
Natasha E. Wade +14 more
wiley +1 more source
Emerging drugs of abuse: current perspectives on synthetic cannabinoids
, 2015 Danièle Debruyne,1,2 Reynald Le Boisselier1 1Centre for Evaluation and Information on Pharmacodependence - Addictovigilance (CEIP-A), 2Toxicology and Pharmacology Laboratory, Department of Pharmacology, University Hospital Centre Côte de ...
Le Boisselier R, Debruyne D
core
The Psychopharmacology of Novel Synthetic Cannabinoids [PDF]
, 2017 Over recent years, the rapid proliferation of novel psychoactive substances has presented significant challenges to health professionals, regulators, and forensic scientists alike.
Kevin, Richard Charles
core
Addiction, EarlyView.Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria +10 more
wiley +1 more source
Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana
, 2017 BACKGROUND AND OBJECTIVES: Data are limited on the behavioral risk correlates of synthetic cannabinoid use. The purpose of this study was to compare the behavioral risk correlates of synthetic cannabinoid use with ...
Heather B. Clayton +4 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr +10 more
wiley +1 more source
Synthetic cannabinoids: emerging drugs of abuse
, 2012 CONTEXTO: A Cannabis sativa (cannabis, maconha, marijuana) é uma droga de abuso com efeitos psicoativos e potencial terapêutico bastante conhecidos.
Linden, Rafael +2 more
core +1 more source